Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Operating Expenses: 2015-2025

Historic Operating Expenses for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to $125.3 million.

  • Intellia Therapeutics' Operating Expenses fell 18.60% to $125.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $536.3 million, marking a year-over-year decrease of 7.67%. This contributed to the annual value of $592.1 million for FY2024, which is 7.36% up from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Operating Expenses is $125.3 million, which was up 0.82% from $124.2 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Operating Expenses registered a high of $155.5 million during Q1 2022, and its lowest value of $52.9 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $142.9 million (2024), whereas its average is $139.1 million.
  • In the last 5 years, Intellia Therapeutics' Operating Expenses soared by 194.11% in 2022 and then declined by 19.89% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Operating Expenses (Quarterly) stood at $93.3 million in 2021, then skyrocketed by 32.58% to $123.7 million in 2022, then climbed by 11.58% to $138.0 million in 2023, then rose by 8.22% to $149.3 million in 2024, then decreased by 18.60% to $125.3 million in 2025.
  • Its last three reported values are $125.3 million in Q3 2025, $124.2 million for Q2 2025, and $137.4 million during Q1 2025.